Education
About Us
Working with TipRanks
Follow Us
Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)
:SUNPHARMA
Vehicle, Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride (Ala Hcl), 20%, Blue Light Photodynamic Therapy Illuminator Device, Blu-U® Model 4170E.
Actinic Keratosis
Phase III
Not Yet Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Aug 20, 2025
―
Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride (Ala Hcl), 20%, Vehicle Containing Excipients Only (Veh) Without Active Ingredient, Blue Light Photodynamic Therapy Illuminator Device, Blu-U® Model 4170E
Actinic Keratosis
Phase III
Not Yet Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Aug 20, 2025
―
Deuruxolitinib
Alopecia Areata
Phase III
Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Jul 29, 2025
―
Trifarotene Cream 0.005%, Aklief® Cream (Trifarotene 0.005%) Us Reference Listed Drug, Aklief® Cream (Trifarotene 50 Mcg/G) Canadian Reference Product
Acne Vulgaris
Phase I
Completed
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
Dec 10, 2024
―
Ruxolitinib Topical Cream 1.5%, Opzelura (Ruxolitinib) Cream
Atopic Dermatitis
Phase I
Completed
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
Nov 02, 2024
―
Clindamycin Phosphate, Adapalene, And Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, Cabtreo Topical Gel
Acne Vulgaris
Phase I
Completed
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
Nov 02, 2024
―
Tildrakizumab 100 Mg
Moderate To Severe Genital Psoriasis
Phase III
Active Not Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
Sep 23, 2024
―
Winlevi (Clascoterone) Cream 1%
Acne Vulgaris
Phase IV
Active Not Recruiting
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
May 10, 2024
―
Winlevi (Clascoterone) 1% Cream
Acne Vulgaris
Phase IV
Completed
A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
May 10, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sun Pharmaceutical Industries Limited (SUNPHARMA) have in its pipeline
SUNPHARMA is currently developing the following drugs: Vehicle, Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride (Ala Hcl), 20%, Blue Light Photodynamic Therapy Illuminator Device, Blu-U® Model 4170E., Reformulated Levulan Kerastick Containing Aminolevulinic Acid Hydrochloride (Ala Hcl), 20%, Vehicle Containing Excipients Only (Veh) Without Active Ingredient, Blue Light Photodynamic Therapy Illuminator Device, Blu-U® Model 4170E, Deuruxolitinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.